Tuberous Sclerosis Complex (TSC)

1. Clinical Overview

Summary

Tuberous Sclerosis Complex (TSC) is an autosomal dominant multisystem genetic disorder caused by mutations in either the TSC1 gene (chromosome 9q34, encoding hamartin) or TSC2 gene (chromosome 16p13, encoding tuberin). These genes normally form a heterodimer complex that negatively regulates the mammalian target of rapamycin (mTOR) signalling pathway, which controls cell growth, proliferation, and differentiation. [1,2]

Loss-of-function mutations result in constitutive mTOR activation, leading to the formation of hamartomas (benign tumour-like malformations) in multiple organ systems including the brain, skin, kidneys, heart, lungs, and eyes. The disease shows nearly 100% penetrance but marked phenotypic variability, even within the same family. [2,3]

TSC affects approximately 1 in 6,000 to 1 in 10,000 live births, with no ethnic or gender predilection. Approximately 30% of cases are familial (inherited from an affected parent), while 70% represent de novo mutations. [1,3] TSC2 mutations generally correlate with more severe phenotypes compared to TSC1 mutations, though significant overlap exists. [4]

The classic Vogt's triad of epilepsy, intellectual disability, and facial angiofibromas (historically termed "adenoma sebaceum") is present in only approximately 30% of patients and should not be relied upon for diagnosis. [2,5] Instead, diagnosis is based on standardized clinical criteria incorporating major and minor features across multiple organ systems, or identification of a pathogenic TSC1 or TSC2 mutation. [1]

Neurological manifestations dominate the clinical picture and morbidity. Epilepsy affects 70-90% of patients, with infantile spasms being the most characteristic seizure type in infancy. [5,6] Cortical tubers, subependymal nodules (SENs), and subependymal giant cell astrocytomas (SEGAs) represent the spectrum of brain lesions. TSC-associated neuropsychiatric disorders (TAND) affect up to 90% of patients and include autism spectrum disorder, attention-deficit/hyperactivity disorder, intellectual disability, anxiety, and depression. [7]

Renal manifestations include angiomyolipomas (80% of adults) and renal cysts. Angiomyolipomas larger than 3-4 cm carry significant risk of spontaneous haemorrhage (Wunderlich syndrome). [8,9] Renal cell carcinoma occurs at increased frequency. Chronic kidney disease and end-stage renal failure represent major causes of mortality in adults. [9]

Cardiac rhabdomyomas are the most common cardiac tumour of infancy and are often the first manifestation detected on prenatal ultrasound. Most regress spontaneously during early childhood but may cause arrhythmias or outflow obstruction in the neonatal period. [10]

Pulmonary lymphangioleiomyomatosis (LAM) affects primarily adult women (30-40% of women with TSC) and is characterized by progressive cystic lung destruction leading to dyspnoea, pneumothorax, and respiratory failure. [11]

Dermatological features are highly characteristic and include hypopigmented macules (ash-leaf spots), facial angiofibromas, Shagreen patches, ungual/periungual fibromas (Koenen tumours), and confetti skin lesions. [1,12]

Management requires lifelong multidisciplinary surveillance and organ-specific interventions. The introduction of mTOR inhibitors (everolimus, sirolimus) has revolutionized treatment, providing targeted disease-modifying therapy for SEGAs, renal angiomyolipomas, and pulmonary LAM. [13,14,15] Vigabatrin is first-line treatment for infantile spasms associated with TSC. [16] Prognosis depends primarily on seizure control and neurological outcomes, with many patients living into adulthood with appropriate care. [2]

Clinical Pearls

Early Recognition Saves Brains: Infantile spasms in TSC are a neurological emergency. Vigabatrin should be initiated immediately—delays in treatment correlate with worse neurodevelopmental outcomes. [16,17]

Wood's Lamp is Essential: Hypopigmented macules (ash-leaf spots) may be the earliest and only visible sign in fair-skinned infants. Always examine with Wood's lamp (ultraviolet light) to reveal these lesions. They are present in 90% of children with TSC. [1,12]

Cardiac Rhabdomyomas = Think TSC: If a fetal or neonatal cardiac mass is detected, TSC should be the leading differential diagnosis. Up to 50% of infants with cardiac rhabdomyomas have TSC. [10]

Prenatal Detection is Common: With routine obstetric ultrasonography, cardiac rhabdomyomas are increasingly detected prenatally, prompting earlier TSC diagnosis and genetic counselling. [10]

SEGA Growth Demands Action: SEGAs near the foramen of Monro can cause acute hydrocephalus. Any SEGA showing growth on serial imaging should prompt treatment with everolimus or neurosurgical consultation. [13,14]

Angiomyolipomas > 4cm Bleed: The risk of spontaneous retroperitoneal haemorrhage increases substantially when renal angiomyolipomas exceed 4 cm in diameter. Prophylactic embolization or mTOR inhibitor therapy should be considered. [8,9]

LAM is Female-Specific: Pulmonary lymphangioleiomyomatosis almost exclusively affects women, typically presenting in the third or fourth decade. Baseline and surveillance chest HRCT should begin at age 18 in all women with TSC. [11]

TAND is Underrecognized: TSC-associated neuropsychiatric disorders affect 90% of patients but only 20% receive appropriate intervention. Annual screening using the TAND checklist is mandatory. [7]

Not All Tubers Cause Seizures: The epileptogenic tuber(s) may be a subset of total tuber burden. Video-EEG telemetry with MEG or PET can identify the focal seizure source, enabling targeted surgical resection (tuberectomy) with 60-70% seizure freedom rates. [18]

Two-Hit Hypothesis: TSC follows Knudson's two-hit hypothesis for tumour formation—patients inherit or develop one germline mutation (first hit), and somatic mutation of the second allele (second hit) in specific cells leads to focal hamartoma development. This explains multifocal but discrete lesions. [19]

---

2. Epidemiology

Incidence and Prevalence

• Incidence: Approximately 1 in 6,000 to 1 in 10,000 live births [1,3]
• Prevalence: Estimated 1 in 15,000 to 1 in 20,000 in the general population [3]
• Gender: Equal male-to-female distribution [3]
• Ethnicity: No significant ethnic or racial predilection [3]

Inheritance Pattern and Genetic Epidemiology

• Autosomal Dominant inheritance with nearly 100% penetrance [1,2]
• De novo mutations: Approximately 70% of cases represent new mutations with no family history [1,3]
• Familial cases: Approximately 30% of cases are inherited from an affected parent [1,3]
• Germline mosaicism: Occurs in approximately 2-6% of apparently unaffected parents, affecting recurrence risk counselling [1]

Genotype-Phenotype Correlations

• TSC1 mutations: Account for 30-40% of definite TSC cases [4]

  • Generally associated with milder phenotype
  • Lower seizure burden
  • Better neurodevelopmental outcomes
  • Fewer SEGAs

• TSC2 mutations: Account for 50-60% of definite TSC cases [4]

  • Associated with more severe phenotype
  • Higher seizure frequency and earlier onset
  • Greater intellectual disability
  • More frequent SEGAs and renal lesions
  • Higher incidence of infantile spasms

• No mutation identified (NMI): 10-20% of clinically definite TSC cases [1,4]

  • May represent large deletions, deep intronic mutations, or mosaicism not detected by standard sequencing

Age-Specific Manifestations

---

3. Molecular Pathophysiology

The TSC1-TSC2-mTOR Signalling Pathway

Normal Physiology

The TSC1 and TSC2 genes encode hamartin and tuberin proteins, respectively, which form a functional heterodimer complex known as the TSC complex. This complex acts as a critical negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1), a serine/threonine protein kinase that serves as a master regulator of cell growth, proliferation, metabolism, and autophagy. [2,20]

Molecular mechanism of TSC complex function:

1. TSC2 (tuberin) possesses GTPase-activating protein (GAP) activity toward the small GTPase Rheb (Ras homolog enriched in brain)
2. The TSC complex converts Rheb-GTP (active) to Rheb-GDP (inactive)
3. Active Rheb-GTP directly activates mTORC1
4. By inactivating Rheb, the TSC complex suppresses mTORC1 activity

Upstream regulation of the TSC complex integrates multiple growth signals:

• Growth factors (insulin, IGF-1) activate PI3K-AKT pathway, which phosphorylates and inhibits TSC2, relieving mTOR suppression
• Energy stress activates AMPK, which phosphorylates and activates TSC2, suppressing mTOR
• Hypoxia stabilizes HIF-1α, which can regulate TSC1/TSC2 expression
• ERK/MAPK pathway phosphorylates TSC2, modulating its activity

Downstream effects of mTORC1 activation:

• Phosphorylates S6 kinase (S6K) → ribosomal protein S6 phosphorylation → increased protein synthesis
• Phosphorylates 4E-BP1 → releases eIF4E → enhanced cap-dependent translation
• Activates lipid synthesis pathways
• Suppresses autophagy
• Promotes cell growth and proliferation

Pathophysiology in TSC

Loss-of-function mutations in either TSC1 or TSC2 disrupt formation of the functional TSC complex, resulting in:

1. Constitutive mTORC1 hyperactivation: Unregulated Rheb-GTP accumulation leads to persistent mTORC1 signalling independent of upstream growth signals [2,20]

2. Uncontrolled cell growth: Enhanced protein synthesis drives cellular hypertrophy, producing characteristic "giant cells" seen histologically in tubers and SEGAs [20]

3. Impaired neuronal differentiation and migration: During brain development, dysregulated mTOR signalling disrupts normal cortical lamination, producing cortical tubers—areas of dysplastic neurons, giant cells, and astrocytes [5,6]

4. Dysregulated proliferation: Increased cell division contributes to hamartoma and tumour formation (SEGAs, angiomyolipomas, rhabdomyomas) [2]

5. Metabolic reprogramming: Enhanced glycolysis, lipogenesis, and nucleotide synthesis support rapid growth [20]

6. Impaired autophagy: Suppression of autophagy may contribute to cellular dysfunction and protein aggregate accumulation [20]

Mechanisms of Organ-Specific Manifestations

Brain Pathology

Cortical Tubers:

• Focal areas of cortical dysplasia resulting from impaired neuronal migration and differentiation during embryogenesis [5,6]
• Histology: disrupted cortical lamination, dysmorphic neurons, giant cells (expressing both neuronal and glial markers), reactive astrocytes
• Tubers are epileptogenic due to abnormal neuronal connectivity and excitability [6]
• Tuber burden and location correlate with neurological severity, though not perfectly predictive [6]

Subependymal Nodules (SENs):

• Hamartomas along the ventricular walls, particularly at the caudothalamic groove [5]
• Composed of abnormal glial cells and giant cells
• Characteristic "candle guttering" appearance on neuroimaging [5]
• Usually benign and non-progressive

Subependymal Giant Cell Astrocytomas (SEGAs):

• WHO Grade I tumours typically arising near the foramen of Monro [13,14]
• Develop in 10-20% of TSC patients, usually in first two decades [13]
• Distinguished from SENs by growth over time (> 1 cm and/or serial enlargement) [13]
• Risk of obstructive hydrocephalus due to strategic location [14]
• Express high levels of activated mTOR pathway markers (phospho-S6, phospho-4E-BP1) [13]

White Matter Abnormalities:

• Radial migration lines extending from periventricular region to cortex
• Represent abnormal glial cell migration tracts [5]

Renal Pathology

Angiomyolipomas (AMLs):

• Benign mesenchymal tumours composed of varying proportions of dysmorphic blood vessels, smooth muscle cells, and adipose tissue [8,9]
• Occur in 70-80% of TSC patients by adulthood [9]
• Often bilateral and multifocal [9]
• Contain abnormal tortuous vessels with deficient elastin, predisposing to aneurysm formation and rupture [8]
• Haemorrhage risk increases with size > 3-4 cm [8]
• Cells express melanocytic markers (HMB-45) despite renal origin [9]

Renal Cysts:

• Occur in 20-30% of TSC patients [9]
• Multiple bilateral cysts may mimic polycystic kidney disease [9]
• Contiguous TSC2-PKD1 deletion syndrome produces severe early-onset polycystic kidney disease [9]

Renal Cell Carcinoma:

• Increased risk (2-4% of TSC patients) compared to general population [9]
• Typically occurs at younger age than sporadic RCC [9]

Cardiac Pathology

Rhabdomyomas:

• Most common cardiac tumour in infancy; 50% occur in TSC patients [10]
• Composed of enlarged, glycogen-rich, immature cardiac myocytes ("spider cells") [10]
• Typically multiple, located in ventricular walls or septum [10]
• Usually detected prenatally or in early infancy [10]
• Spontaneous regression common (50-75% decrease in size by age 2-4 years) [10]
• Mechanism of regression unclear; may relate to decreasing mTOR activity with age [10]

Pulmonary Pathology

Lymphangioleiomyomatosis (LAM):

• Progressive cystic lung disease affecting 30-40% of adult women with TSC [11]
• Characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) along airways, blood vessels, and lymphatics [11]
• LAM cells express smooth muscle markers (smooth muscle actin) and melanocytic markers (HMB-45) [11]
• Cystic lung destruction from airway obstruction and proteolytic activity [11]
• Chylous effusions from lymphatic obstruction [11]
• Pneumothorax from cyst rupture [11]
• Nearly exclusively female, suggesting hormonal influence; estrogen may promote LAM cell proliferation [11]

Dermatological Pathology

Hypopigmented Macules (Ash-Leaf Spots):

• Result from decreased melanin production in affected melanocytes [12]
• Earliest manifestation (present at birth or early infancy) [12]
• Lance-ovate, confetti, or polygonal shapes [12]

Facial Angiofibromas:

• Develop age 2-5 years in 75% of patients [12]
• Composed of fibrous tissue and vascular proliferation [12]
• Nasolabial and malar distribution [12]

Shagreen Patches:

• Connective tissue nevi, typically lumbar region [12]
• Thickened collagen bundles in dermis [12]

Ungual/Periungual Fibromas (Koenen Tumours):

• Develop in adolescence/adulthood [12]
• Fibroblastic proliferation beneath or adjacent to nail plate [12]

Molecular Basis of mTOR Inhibitor Therapy

The pathophysiological mechanism of TSC directly informs targeted therapy. Rapamycin (sirolimus) and its analog everolimus function as allosteric mTORC1 inhibitors:

1. Mechanism of action: Rapamycin binds to the immunophilin FKBP12; the rapamycin-FKBP12 complex then binds to and inhibits mTORC1 [13,15]

2. "Disease-modifying" therapy: By suppressing the hyperactive mTOR pathway, rapalogs directly address the molecular defect caused by TSC1/TSC2 loss [13,15]

3. Clinical efficacy:

   • SEGA: Everolimus produces > 50% volume reduction in majority of SEGAs, avoiding neurosurgery in most cases [13,14]
   • Renal AMLs: Everolimus/sirolimus reduce AML volume by 40-50%, decreasing haemorrhage risk [15]
   • Pulmonary LAM: Sirolimus stabilizes lung function decline [11]
   • Facial angiofibromas: Topical sirolimus significantly improves cutaneous lesions [12]
   • Epilepsy: Emerging evidence for everolimus as adjunctive antiseizure medication [21]

4. Limitations: Treatment is suppressive, not curative—lesion regrowth typically occurs upon discontinuation, necessitating long-term therapy [13,14,15]

---

4. Diagnostic Criteria and Clinical Features

Updated International TSC Diagnostic Criteria (2021)

The 2021 International TSC Consensus Conference updated diagnostic criteria to incorporate advances in genetics and neuroimaging. [1]

Definite TSC:

• Two major features, OR
• One major feature + two or more minor features, OR
• Identification of a pathogenic TSC1 or TSC2 mutation in DNA from normal tissue (blood or buccal swab)

Possible TSC:

• One major feature, OR
• Two or more minor features

Important notes:

• Lymphangioleiomyomatosis (LAM) + renal angiomyolipomas together constitute one major feature, not two
• Genetic testing is definitive—a single pathogenic mutation establishes diagnosis regardless of clinical manifestations [1]
• Approximately 10-20% of clinically definite TSC patients have no identifiable mutation by standard testing [1,4]

Major Diagnostic Features (11 Total)

1. Hypomelanotic Macules (≥3, at least 5 mm diameter)

• Appearance: Well-demarcated, hypopigmented (not depigmented) macules [12]
• Shapes: Lance-ovate ("ash-leaf"), confetti (small 1-2 mm), polygonal
• Detection: Wood's lamp examination (ultraviolet light enhances visualization) [12]
• Prevalence: 90% of children with TSC [12]
• Onset: Present at birth or within first year [12]
• Distribution: Trunk and extremities; any location possible
• Differential: Nevus depigmentosus, vitiligo, nevus anemicus, hypopigmented tinea versicolor

2. Angiofibromas (≥3) or Fibrous Cephalic Plaque

• Angiofibromas:

  • Smooth, pink-to-red papules in nasolabial folds, cheeks, chin [12]
  • Historically termed "adenoma sebaceum" (misnomer—not adenomas) [12]
  • Develop age 2-5 years; present in 75% by adolescence [12]
  • Increase with age; may become disfiguring [12]

• Fibrous Cephalic Plaque:

  • Elevated, flesh-colored plaque, typically forehead or scalp [12]
  • Present in 20-30% of TSC patients [12]
  • May be present at birth [12]

3. Ungual Fibromas (≥2)

• Alternative term: Koenen tumours [12]
• Appearance: Flesh-colored periungual or subungual fibromas [12]
• Distribution: Toenails more common than fingernails [12]
• Onset: Late childhood, adolescence, or adulthood [12]
• Prevalence: 20-50% of adults with TSC [12]
• Clinical significance: May cause nail dystrophy or pain [12]

4. Shagreen Patch

• Appearance: Flesh-colored, elevated, leathery plaque with "orange-peel" texture [12]
• Location: Typically lumbosacral region [12]
• Onset: Childhood [12]
• Prevalence: 20-40% of TSC patients [12]
• Histology: Connective tissue nevus with thickened collagen bundles [12]

5. Multiple Retinal Hamartomas

• Appearance: Elevated, non-calcified lesions; or flat, calcified "mulberry" lesions [1]
• Location: Typically peripheral retina; may involve optic disc [1]
• Prevalence: 30-50% of TSC patients [1]
• Clinical significance: Usually asymptomatic; rarely cause vision loss [1]
• Differential: Retinoblastoma (unilateral, calcified, progressive)

6. Cortical Dysplasias (Tubers)

• Imaging:

  • "MRI: Hyperintense on T2/FLAIR; may show hypointense on T1 [5]"
  • Number ranges from none to > 20 [5]
  • Distributed throughout cerebral cortex; often involve frontal and parietal regions [5]

• Clinical correlation:

  • Tuber burden correlates weakly with seizure severity [6]
  • Specific tuber(s) may be epileptogenic focus [6]
  • Not all tubers cause seizures [6]

7. Subependymal Nodules (SENs)

• Imaging:

  • Nodular lesions protruding into lateral ventricles [5]
  • "Typical location: caudothalamic groove [5]"
  • "Candle guttering" appearance [5]
  • May calcify over time [5]

• Prevalence: 80-90% of TSC patients [5]

• Natural history: Generally stable; non-progressive [5]

8. Subependymal Giant Cell Astrocytoma (SEGA)

• Definition: Lesion > 1 cm near caudothalamic groove that shows serial growth [13]
• Prevalence: 10-20% of TSC patients [13]
• Age: Most develop in first 20 years; peak age 8-18 years [13]
• Location: Typically near foramen of Monro [13,14]
• Imaging: Enhances with gadolinium; may show cystic components [13]
• Complications: Obstructive hydrocephalus from foramen of Monro obstruction [14]
• Histology: WHO Grade I; composed of large gemistocytic cells [13]

9. Cardiac Rhabdomyoma

• Prevalence: 50-70% of TSC infants [10]
• Detection: Often prenatal or neonatal echocardiography [10]
• Location: Ventricular walls, septum [10]
• Appearance: Echogenic intracardiac masses; often multiple [10]
• Complications: Arrhythmias, outflow obstruction (rare) [10]
• Natural history: Spontaneous regression in 50-75% by age 2-4 years [10]

10. Renal Angiomyolipomas (≥2)

• Prevalence: 70-80% of adults with TSC [9]

• Age: Increase in size and number with age [9]

• Imaging:

  • "Ultrasound: Hyperechoic masses due to fat content [9]"
  • "CT: Low attenuation (negative Hounsfield units) from fat [9]"
  • "MRI: High signal on T1 and T2; signal dropout on fat-suppressed sequences [9]"

• Complications:

  • Spontaneous haemorrhage (Wunderlich syndrome) [8]
  • Risk increases with lesions > 3-4 cm [8]
  • Chronic kidney disease from replacement of renal parenchyma [9]

11. Lymphangioleiomyomatosis (LAM)

• Prevalence: 30-40% of adult women with TSC; rare in men [11]

• Age: Typically presents ages 20-40 years [11]

• Imaging:

  • "Chest HRCT: Diffuse thin-walled cysts; round, well-defined; usually less than 3 cm [11]"
  • Uniform distribution throughout both lungs [11]

• Clinical features:

  • Progressive dyspnoea [11]
  • Recurrent pneumothorax (50-80% of patients) [11]
  • Chylous pleural effusion (10-20%) [11]

• Diagnosis:

  • HRCT findings + TSC diagnosis is sufficient [11]
  • Lung biopsy rarely needed in TSC-LAM [11]

Important diagnostic note: LAM in the presence of TSC constitutes one major feature. If a patient also has renal angiomyolipomas, this combination counts as one major feature (not two). [1]

Minor Diagnostic Features (6 Total)

1. "Confetti" skin lesions: Numerous small (1-2 mm) hypopigmented macules scattered on arms and legs [1,12]

2. Dental enamel pits (> 3): Small pits in tooth enamel; require professional dental examination [1]

3. Intraoral fibromas (≥2): Gingival fibromas [1,12]

4. Retinal achromic patch: Single or multiple [1]

5. Multiple renal cysts: Defined as > 3 renal cysts [1,9]

6. Nonrenal hamartomas: Hepatic, splenic, or other organ hamartomas documented by biopsy or imaging [1]

---

5. Clinical Presentation by Organ System

Neurological Manifestations

Epilepsy (70-90% of TSC Patients)

Infantile Spasms (West Syndrome):

• Most characteristic seizure type in TSC infancy [6,16]
• Peak age: 3-12 months [16]
• Presentation: Clustered spasms (flexor, extensor, or mixed); often on awakening [16]
• EEG: Hypsarrhythmia (chaotic high-voltage slow waves with multifocal spikes) [16]
• Prognosis:
  • Treatment delay correlates with worse neurodevelopmental outcomes [17]
  • Early vigabatrin treatment improves long-term cognitive outcomes [16,17]
  • 60-80% progress to other seizure types [6]

Focal Seizures:

• Most common seizure type in older children and adults with TSC [6]
• Arise from epileptogenic tuber(s) [6]
• Semiology depends on tuber location [6]
• May secondarily generalize [6]

Other Seizure Types:

• Generalized tonic-clonic seizures [6]
• Atonic seizures [6]
• Absence seizures (less common) [6]

Refractory Epilepsy:

• 60-80% of TSC patients have drug-resistant epilepsy [6,18]
• Multiple antiseizure medications often required [6]
• Surgical options: focal resection (tuberectomy), lobectomy, hemispherectomy, vagal nerve stimulation, responsive neurostimulation [18]
• Presurgical evaluation: video-EEG, MEG, PET, ictal SPECT to localize epileptogenic zone [18]
• Surgical outcomes: 50-70% seizure freedom if single epileptogenic tuber identified and resected [18]

TSC-Associated Neuropsychiatric Disorders (TAND)

Prevalence: 90% of TSC patients have at least one TAND manifestation [7] Undertreatment: Only 20% receive appropriate intervention [7]

TAND Domains:

1. Behavioural:

   • Aggression, self-injury, impulsivity [7]
   • Sleep disturbances (very common; 30-60% of children) [7]
   • Overactivity, tantrums [7]

2. Psychiatric:

   • Autism spectrum disorder (40-50%) [7]
   • ADHD (30-50%) [7]
   • Anxiety disorders (30-50%) [7]
   • Depression (30% of adults) [7]
   • Psychosis (rare; less than 5%) [7]

3. Intellectual:

   • Intellectual disability in 40-60% [7]
   • Range: mild to severe/profound [7]
   • Borderline intellectual functioning in 10-20% [7]
   • Normal IQ in 30-40% [7]
   • IQ inversely correlates with infantile spasms history and seizure burden [7,17]

4. Academic:

   • Specific learning disabilities even in normal IQ [7]
   • Executive function deficits [7]
   • Memory impairments [7]

5. Neuropsychological:

   • Deficits in working memory, processing speed, visuospatial function [7]

6. Psychosocial:

   • Social communication difficulties [7]
   • Family burden and caregiver stress [7]

TAND Screening:

• Annual TAND checklist recommended for all TSC patients [1,7]
• Comprehensive neuropsychological evaluation at key developmental stages [7]
• Early intervention and educational support improve outcomes [7]

Renal Manifestations

Angiomyolipomas (see Major Features above):

• Major cause of morbidity and mortality in adults [9]
• Haemorrhage risk necessitates surveillance [8,9]
• Intervention thresholds: size > 3-4 cm, rapid growth, symptomatic [8,9]

Renal Cysts:

• Usually asymptomatic [9]
• May rarely cause haematuria or pain [9]
• Can progress to chronic kidney disease [9]

Renal Cell Carcinoma:

• Increased incidence (2-4% of TSC adults) [9]
• Earlier age of onset than sporadic RCC [9]
• Surveillance imaging detects most cases early [9]

Chronic Kidney Disease and End-Stage Renal Disease:

• Result from replacement of functional parenchyma by AMLs and cysts [9]
• Major cause of mortality in adults with TSC [9]

Cardiac Manifestations

Cardiac Rhabdomyomas (see Major Features above):

• Most regress spontaneously [10]
• Rarely cause significant symptoms requiring intervention [10]

Arrhythmias:

• Wolff-Parkinson-White syndrome reported in TSC [10]
• Ventricular pre-excitation [10]

Pulmonary Manifestations

Lymphangioleiomyomatosis (LAM) (see Major Features above):

• Progressive dyspnoea, exercise intolerance [11]
• Pneumothorax (may be recurrent) [11]
• Chylous effusions [11]
• Pulmonary function tests show obstructive pattern with reduced DLCO [11]

Ophthalmologic Manifestations

Retinal Hamartomas (see Major Features above):

• Usually asymptomatic [1]
• Rarely cause vision impairment (if involving macula or causing vitreous haemorrhage) [1]

Retinal Achromic Patch (minor feature):

• Flat, hypopigmented retinal lesion [1]

Other Rare Findings:

• Papilledema (if SEGA causes hydrocephalus) [1]
• Visual field defects from cortical tuber involvement of occipital cortex [1]

Dermatological Manifestations

(See Major and Minor Features above for detailed description)

Additional Features:

• Forehead plaque: Connective tissue nevus on forehead [12]
• Poliosis: Localized patch of white hair [12]
• Café-au-lait macules: May occur but not specific to TSC [12]

Gastrointestinal and Hepatic Manifestations

• Hepatic angiomyolipomas: Rare; similar composition to renal AMLs [1]
• Rectal polyps: Increased incidence [1]
• Other hamartomas: Splenic, pancreatic (rare) [1]

Dental Manifestations

• Dental enamel pits: Minor diagnostic feature [1]
• Gingival fibromas: Minor diagnostic feature [1]

---

6. Investigations and Surveillance

Genetic Testing

Indications

• Confirm diagnosis in patients meeting clinical criteria [1]
• Evaluate patients with single major feature or multiple minor features [1]
• Family screening of at-risk relatives [1]
• Prenatal diagnosis in families with known pathogenic mutation [1]

Methodology

• Sequencing: TSC1 and TSC2 gene full sequencing [1]
• Deletion/duplication analysis: MLPA or array-CGH to detect large deletions [1]
• Detection rate: 75-90% in patients meeting definite diagnostic criteria [1,4]

Interpretation

• Pathogenic TSC1 or TSC2 mutation establishes definite TSC diagnosis regardless of clinical features [1]
• Variants of uncertain significance (VUS) require functional studies or family segregation analysis [1]
• No mutation identified (NMI) in 10-20% of clinically definite TSC—does not exclude diagnosis [1,4]

Baseline Evaluation at Diagnosis

Recommended baseline assessment for all newly diagnosed TSC patients: [1]

Ongoing Surveillance Protocol

The 2021 International TSC Consensus guidelines recommend lifelong surveillance: [1]

Brain Surveillance

SEGA growth criteria requiring intervention: [13,14]

• Serial enlargement on consecutive MRI scans
• Development of periventricular edema
• New or worsening hydrocephalus
• New neurological symptoms

Renal Surveillance

Alternative: Renal ultrasound may be used but MRI preferred for accuracy and RCC detection [1,9]

Pulmonary Surveillance (Women Only)

Symptoms prompting evaluation: Dyspnoea, pneumothorax, chylous effusion [11]

Cardiac Surveillance

Dermatologic Surveillance

• Annual skin examination (may be by primary care or dermatology) [1,12]
• Document progression of angiofibromas, ungual fibromas [12]

Ophthalmologic Surveillance

• Baseline dilated fundoscopy [1]
• Repeat if visual symptoms develop [1]
• Routine screening not required if baseline normal and asymptomatic [1]

Neuropsychiatric Surveillance (TAND)

• Annual TAND checklist [1,7]
• Comprehensive neuropsychological evaluation at: [7]
  • Diagnosis
  • School entry (age 5-6)
  • Transition points (ages 9-10, 12-13, 16-17)
  • As clinically indicated
• Sleep assessment annually in children [7]

Diagnostic Neuroimaging Characteristics

MRI Brain Findings in TSC

Cortical Tubers:

• T1: Hypointense or isointense [5]
• T2/FLAIR: Hyperintense [5]
• Enhancement: Usually no enhancement (if enhancement present, consider SEGA or other pathology) [5]
• Distribution: Cerebral cortex; frontal and parietal lobes most common [5]

Subependymal Nodules:

• Location: Along lateral ventricles, especially caudothalamic groove [5]
• T1: Isointense to hyperintense (if calcified) [5]
• T2: Hypointense to isointense (if calcified) [5]
• Enhancement: May enhance with gadolinium [5]
• "Candle guttering" appearance [5]

Subependymal Giant Cell Astrocytomas (SEGAs):

• Location: Near foramen of Monro [5,13]
• Size: > 1 cm [13]
• T1: Isointense to hypointense [13]
• T2: Hyperintense [13]
• Enhancement: Avid enhancement with gadolinium [13]
• May show cystic components [13]
• Serial growth on consecutive imaging distinguishes from stable SEN [13]

White Matter Radial Migration Lines:

• T2/FLAIR: Hyperintense linear tracts extending from ventricle to cortex [5]

CT Brain Findings

• Calcified subependymal nodules (easier to detect on CT than MRI) [5]
• Cortical tubers may be hypodense [5]
• Less sensitive than MRI for tuber detection [5]

Chest HRCT Findings in LAM

• Diffuse, bilateral, thin-walled cysts [11]
• Round, well-defined margins [11]
• Relatively uniform size (typically less than 3 cm) [11]
• Uniform distribution throughout all lung zones [11]
• No zonal predominance (differentiates from smoking-related emphysema) [11]

---

7. Management

Overview of Management Principles

Management of TSC requires lifelong multidisciplinary care involving: [1]

• Neurology (epilepsy, SEGA, TAND)
• Nephrology (renal lesions, CKD)
• Pulmonology (LAM)
• Cardiology (rhabdomyomas, arrhythmias)
• Dermatology (cutaneous lesions)
• Ophthalmology (retinal hamartomas)
• Genetics (counselling, family screening)
• Neuropsychology/psychiatry (TAND)
• Neurosurgery (SEGA, epilepsy surgery)
• Interventional radiology (AML embolization)

Goals:

1. Monitor for and treat organ-specific complications
2. Optimize seizure control and neurodevelopmental outcomes
3. Prevent life-threatening complications (SEGA hydrocephalus, AML haemorrhage)
4. Address TAND manifestations
5. Provide genetic counselling and family screening
6. Coordinate care across specialties

Management Algorithm

SUSPECTED OR CONFIRMED TSC
         ↓
BASELINE COMPREHENSIVE EVALUATION
- Brain MRI + EEG
- Renal imaging (MRI/CT)
- Echocardiogram (paediatric)
- Chest HRCT (women ≥18)
- Ophthalmology + Dermatology
- TAND checklist
- Genetic testing + counselling
         ↓
INITIATE SURVEILLANCE PROTOCOL
- Brain MRI every 1-3 years
- Renal MRI every 1-3 years
- Pulmonary surveillance (women)
- Annual TAND screening
         ↓
MANAGE ORGAN-SPECIFIC MANIFESTATIONS
         ↓
    ┌────────┴────────┬──────────────┬──────────────┐
EPILEPSY          SEGA          RENAL AML      PULMONARY LAM
    ↓                 ↓                ↓                ↓
Infantile Spasms: Growing/        AML > 3
cm:      Progressive LAM:
VIGABATRIN       Symptomatic:     EVEROLIMUS     SIROLIMUS
                 EVEROLIMUS       or             
Focal Seizures:  or               EMBOLIZATION   Pneumothorax:
ASMs             SURGERY                         PLEURODESIS
                                  Haemorrhage:   
Refractory:                       EMBOLIZATION   End-stage:
SURGERY                           ± SURGERY      TRANSPLANT
VNS/RNS
Ketogenic Diet
    ↓
TAND SCREENING & INTERVENTION
- ASD: Behavioural therapy, special education
- ADHD: Stimulants, behavioural intervention
- Anxiety/Depression: CBT, SSRIs
- Sleep: Melatonin, sleep hygiene
- Educational support (IEP/504)

Epilepsy Management

Infantile Spasms (West Syndrome)

First-Line Treatment: Vigabatrin [16,17]

• Evidence: FSGE study demonstrated vigabatrin superior to other treatments for infantile spasms in TSC [16]
• Efficacy: 70-95% cessation of spasms within 2 weeks [16,17]
• Dosing: 50-150 mg/kg/day divided twice daily; titrate rapidly [16]
• Monitoring:
  • Ophthalmologic examination (visual field testing) every 3 months due to risk of peripheral retinal toxicity [16]
  • Difficult in infants; may use electroretinography [16]
• Outcome: Early vigabatrin treatment improves long-term neurodevelopmental outcomes [17]

Alternative Treatments if Vigabatrin Fails:

• ACTH or high-dose corticosteroids [16]
• Combination therapy (vigabatrin + corticosteroids) [16]
• Other ASMs (topiramate, zonisamide) [16]

Urgent Treatment Principle: Infantile spasms constitute a neurological emergency—treatment delay worsens long-term cognitive prognosis [17]

Focal and Generalized Seizures

Antiseizure Medications (ASMs):

No single ASM is universally effective; treatment individualized based on seizure type, tolerability, and comorbidities. [6]

Commonly used ASMs in TSC epilepsy:

• Levetiracetam: Broad-spectrum; well-tolerated; no drug interactions [6]
• Oxcarbazepine: Effective for focal seizures [6]
• Carbamazepine: Focal seizures; drug interactions [6]
• Valproic acid: Broad-spectrum; monitor for hepatotoxicity [6]
• Lamotrigine: Broad-spectrum; slow titration required [6]
• Topiramate: Broad-spectrum; cognitive side effects may be limiting [6]
• Zonisamide: Broad-spectrum [6]
• Lacosamide: Focal seizures [6]

Polytherapy: Most TSC patients require multiple ASMs [6]

Everolimus as Adjunctive ASM

• Evidence: Phase 3 trials (EXIST-3) demonstrated everolimus reduces seizure frequency in TSC [21]
• Indication: Adjunctive treatment for focal-onset seizures in TSC patients ≥2 years [21]
• Efficacy: ≥50% seizure reduction in ~40% of patients [21]
• Dosing: Target trough level 5-15 ng/mL [21]
• Consideration: May benefit patients with SEGA or AML requiring everolimus for those indications [21]

Refractory Epilepsy: Surgical Options

Indications for Epilepsy Surgery: [18]

• Drug-resistant epilepsy (failure of ≥2 ASMs)
• Identifiable epileptogenic focus
• Focal seizures amenable to resection

Presurgical Evaluation: [18]

• Video-EEG telemetry: Capture and characterize seizures; localize ictal onset
• MEG (magnetoencephalography): Non-invasive localization of interictal and ictal activity
• PET (18F-FDG): Identify hypometabolic tuber(s) representing epileptogenic zone
• Ictal SPECT: Demonstrate hyperperfusion during seizure
• Neuropsychological testing: Assess cognitive risks
• Functional MRI: Language and motor mapping
• Invasive EEG (stereo-EEG or subdural grids) if non-invasive localization inconclusive

Surgical Procedures: [18]

1. Focal Resection (Tuberectomy):

   • Remove single epileptogenic tuber and surrounding epileptogenic tissue
   • Best outcomes: 60-70% seizure freedom if single focus identified [18]
   • Lower seizure freedom if multifocal or if electrographic abnormalities extend beyond resected area [18]

2. Lobectomy/Multilobar Resection:

   • If multiple adjacent tubers in one lobe are epileptogenic
   • Outcomes similar to tuberectomy if clear localization [18]

3. Hemispherectomy:

   • Rarely indicated; for hemispheric epilepsy with contralateral hemiparesis
   • High seizure freedom rates (70-80%) in selected cases [18]

4. Vagal Nerve Stimulation (VNS):

   • Palliative option for multifocal epilepsy not amenable to resection [18]
   • ~50% of patients achieve ≥50% seizure reduction [18]
   • Mechanism: Intermittent vagal nerve stimulation modulates seizure threshold [18]

5. Responsive Neurostimulation (RNS):

   • Closed-loop device detects seizure onset and delivers targeted stimulation
   • Option for eloquent cortex or multifocal seizures [18]

6. Ketogenic Diet:

   • High-fat, low-carbohydrate diet inducing ketosis
   • Effective in paediatric refractory epilepsy, including TSC [18]
   • 30-50% achieve ≥50% seizure reduction [18]
   • Requires close dietary and metabolic monitoring [18]

SEGA Management

Indications for Treatment

• SEGA showing serial growth on consecutive MRI scans [13,14]
• SEGA ≥1 cm near foramen of Monro (even if stable) [13,14]
• New or worsening ventricular enlargement/hydrocephalus [14]
• New neurological symptoms attributable to SEGA (headache, vision changes, cognitive decline) [14]

First-Line: mTOR Inhibitor Therapy

Everolimus (Afinitor®, Votubia®): [13,14,15]

• Mechanism: Allosteric mTORC1 inhibitor (see Pathophysiology section)
• Evidence: EXIST-1 trial demonstrated everolimus produced SEGA response (≥50% volume reduction) in 35% at 6 months, 42% at final analysis [13]
• Efficacy:
  • ≥50% volume reduction in 35-57% [13,14]
  • Stable disease in most others [13,14]
  • Progression rare during treatment [13,14]
  • Symptom improvement (headache resolution, cognitive improvement) [14]
• Dosing:
  • "Target trough blood level: 5-15 ng/mL [13,14]"
  • "Starting dose: 4.5 mg/m² PO daily [14]"
  • Titrate based on trough levels and tolerability [14]
• Monitoring:
  • Trough everolimus levels (2 weeks after initiation, then every 3-6 months) [14]
  • Brain MRI every 6-12 months to assess response [13,14]
  • CBC, renal function, liver function, lipid panel, urinalysis at baseline and regularly [14]
• Duration: Typically long-term (often indefinite); SEGA regrowth common upon discontinuation [13,14]

Adverse Effects: [14,15]

• Stomatitis/mucositis (most common; 30-50%)
• Infections (upper respiratory, sinusitis, UTI)
• Hyperlipidemia
• Cytopenias (anemia, lymphopenia, thrombocytopenia)
• Menstrual irregularities
• Impaired wound healing
• Pneumonitis (rare but serious; 2-5%)
• Immunosuppression (live vaccines contraindicated)

Management of Adverse Effects: [14,15]

• Stomatitis: Topical corticosteroid mouth rinse, oral analgesics, dose reduction if severe
• Infections: Appropriate antimicrobials; prophylaxis not routinely recommended
• Hyperlipidemia: Statins or fibrates if indicated
• Pneumonitis: Discontinue everolimus; corticosteroids for severe cases

Second-Line: Neurosurgical Resection

Indications: [14]

• Acute hydrocephalus with rapid neurological deterioration (emergent surgery)
• Failure of or contraindication to mTOR inhibitor
• Patient/family preference
• Complete resection technically feasible

Surgical Approaches: [14]

• Transcallosal (interhemispheric) approach
• Transcortical approach

Outcomes: [14]

• Gross total resection curative (no recurrence) in most cases
• Subtotal resection may require additional treatment
• Surgical morbidity: hemiparesis, memory deficits, fornix injury, intraventricular haemorrhage

Modern Paradigm: Everolimus is now first-line for most SEGAs; surgery reserved for acute hydrocephalus or everolimus failure. [13,14]

Ventriculoperitoneal Shunt

• Role: Temporizing measure for hydrocephalus if SEGA resection delayed or patient unfit for surgery
• Limitation: Does not address SEGA growth; SEGA treatment still required [14]

Renal Angiomyolipoma Management

Observation (Asymptomatic AML less than 3 cm)

• Continue surveillance imaging every 1-3 years [9]
• Patient education regarding haemorrhage symptoms (sudden flank pain, haematuria, hypotension) [9]

Intervention Indications

• AML ≥3-4 cm (increased haemorrhage risk) [8,9]
• Rapid AML growth [9]
• Symptomatic AML (pain, haematuria) [9]
• Acute haemorrhage [8]

First-Line Medical Management: mTOR Inhibitors

Everolimus or Sirolimus: [9,15]

• Evidence: EXIST-2 trial demonstrated everolimus reduced AML volume by ≥50% in 42% of patients vs. 0% with placebo [15]
• Efficacy:
  • "Mean AML volume reduction: 40-50% [15]"
  • Reduction in haemorrhage risk [9,15]
  • Improved renal function preservation [9]
• Dosing:
  • Everolimus target trough 5-15 ng/mL [15]
  • Sirolimus target trough 5-15 ng/mL [9]
• Duration: Long-term therapy; AML regrowth upon discontinuation [15]
• Monitoring: Same as for SEGA treatment (see above)

Limitations: [15]

• Suppressive, not curative
• Requires indefinite treatment
• Adverse effects (see SEGA section)
• Cost

Interventional: Selective Arterial Embolization

Indications: [8,9]

• Acute haemorrhage (Wunderlich syndrome)
• Large AML (> 4 cm) if patient unsuitable for or declines mTOR inhibitor
• Prophylactic embolization for very large or aneurysmal AML

Procedure: [8,9]

• Angiography to identify feeding vessels
• Superselective catheterization
• Embolization with coils, particles, or liquid agents (Onyx)
• Goal: Devascularize AML while preserving normal renal parenchyma

Outcomes: [8,9]

• Effective for acute haemorrhage control (> 90% success)
• Reduces AML size by 30-60%
• Nephron-sparing (preserves renal function better than nephrectomy)

Complications: [8,9]

• Post-embolization syndrome (fever, pain, nausea; common but self-limited)
• Renal infarction if non-selective embolization
• Recurrence possible (AML may recruit new vessels)

Surgical: Partial or Total Nephrectomy

Indications: [9]

• Massive haemorrhage uncontrolled by embolization (rare)
• Suspected malignancy (renal cell carcinoma)
• Failed embolization and mTOR inhibitor therapy

Approach: [9]

• Partial nephrectomy (nephron-sparing) preferred if technically feasible
• Total nephrectomy reserved for non-salvageable kidney

Limitation: Nephrectomy undesirable in TSC due to bilateral disease and risk of chronic kidney disease [9]

Renal Cell Carcinoma Management

• Standard oncologic principles apply [9]
• Partial nephrectomy preferred to preserve renal function [9]
• Surveillance imaging critical for early detection [9]

Pulmonary LAM Management

Medical Management: Sirolimus (Rapamycin)

Evidence: MILES trial demonstrated sirolimus stabilized lung function in LAM [11]

Indications: [11]

• Progressive LAM (declining FEV1)
• Symptomatic LAM (dyspnoea, impaired quality of life)

Efficacy: [11]

• Stabilizes FEV1 decline
• Improves FEV1 in some patients
• Reduces serum VEGF-D levels (biomarker)
• Improves quality of life

Dosing: [11]

• Target sirolimus trough: 5-15 ng/mL
• Starting dose: 1-2 mg daily, adjusted to trough level

Monitoring: [11]

• Sirolimus trough levels
• Pulmonary function tests every 6-12 months
• Adverse effects (similar to everolimus; see SEGA section)

Duration: Long-term therapy; lung function decline may resume upon discontinuation [11]

Bronchodilators

• May provide symptomatic relief if airflow obstruction present [11]
• Beta-agonists, anticholinergics as in COPD/asthma [11]

Pneumothorax Management

Small Pneumothorax (less than 20%): [11]

• Observation vs. simple aspiration
• High recurrence rate (50-80%) [11]

Large Pneumothorax: [11]

• Tube thoracostomy
• Chemical or surgical pleurodesis recommended to prevent recurrence [11]

Recurrent Pneumothorax: [11]

• Pleurodesis (talc, doxycycline) [11]
• Video-assisted thoracoscopic surgery (VATS) with pleurectomy or pleural abrasion [11]

Important: Pleurodesis may complicate future lung transplantation; discuss with transplant team if end-stage disease anticipated [11]

Chylous Effusion Management

• Thoracentesis for symptomatic relief [11]
• Low-fat diet (reduce chyle production) [11]
• Pleurodesis if recurrent [11]
• Rarely, thoracic duct ligation or embolization [11]

Lung Transplantation

Indications: [11]

• End-stage LAM with severe respiratory failure
• FEV1 less than 30% predicted or rapidly declining
• Hypoxemia requiring continuous supplemental oxygen
• Severely impaired quality of life despite medical therapy

Outcomes: [11]

• 5-year survival post-transplant: ~50-60%
• LAM can recur in transplanted lung (rare, due to metastasis of LAM cells)

TSC-Specific Consideration: Multisystem TSC manifestations (renal, neurological) must be stable and well-controlled for transplant candidacy [11]

Cardiac Rhabdomyoma Management

Observation (Most Cases)

• Natural history: Spontaneous regression in 50-75% by age 2-4 years [10]
• Monitoring: Serial echocardiography every 1-3 years until regression documented [10]

Medical Management

• Antiarrhythmics: If arrhythmias present (e.g., SVT, Wolff-Parkinson-White syndrome) [10]
• mTOR inhibitors: Case reports suggest everolimus/sirolimus may reduce rhabdomyoma size, but evidence limited; not standard therapy [10]

Surgical Resection

Indications (Rare): [10]

• Severe outflow obstruction causing hemodynamic compromise
• Life-threatening arrhythmias refractory to medical management
• Failure to regress causing symptoms

Timing: Surgical resection usually avoided due to high spontaneous regression rate [10]

Dermatologic Management

Facial Angiofibromas

Topical Sirolimus (Rapamycin): [12]

• Efficacy: 0.2-0.4% sirolimus gel applied daily produces significant improvement (30-50% reduction) in ~80% [12]
• Advantage: Non-invasive; well-tolerated [12]
• Duration: Requires continued application; recurrence upon discontinuation [12]

Laser Therapy: [12]

• Pulsed-dye laser, CO2 laser, or erbium:YAG laser
• Multiple sessions required
• Risk of scarring
• Recurrence common

Dermabrasion: [12]

• Mechanical abrasion of lesions
• May improve cosmesis
• Recurrence common

Surgical Excision: [12]

• Reserved for large, disfiguring lesions
• Risk of scarring

Ungual Fibromas (Koenen Tumours)

• Observation: If asymptomatic [12]
• Surgical excision: If painful or causing nail dystrophy [12]
• Topical sirolimus: May reduce size [12]

Hypopigmented Macules

• No treatment required; benign [12]
• Cosmetic camouflage if desired [12]

Shagreen Patch

• No treatment required; benign [12]
• Surgical excision for cosmesis rarely pursued [12]

TAND Management

Screening and Assessment

• Annual TAND checklist for all TSC patients [1,7]
• Comprehensive neuropsychological evaluation at key ages (see Surveillance section) [7]
• Sleep assessment (especially in children) [7]

Behavioural Interventions

Autism Spectrum Disorder: [7]

• Early intensive behavioural intervention (ABA)
• Speech and language therapy
• Occupational therapy
• Social skills training
• Special education services (IEP)

ADHD: [7]

• Behavioural interventions (parent training, classroom accommodations)
• Stimulant medications (methylphenidate, amphetamines)
• Non-stimulant medications (atomoxetine, guanfacine) if stimulants not tolerated

Anxiety Disorders: [7]

• Cognitive-behavioural therapy (CBT)
• SSRIs (sertraline, fluoxetine, escitalopram)

Depression: [7]

• Psychotherapy (CBT, interpersonal therapy)
• SSRIs or SNRIs
• Close monitoring for suicidality

Aggression, Self-Injury, Severe Behavioural Disturbance: [7]

• Functional behavioural analysis
• Behavioural interventions
• Pharmacotherapy: risperidone, aripiprazole (atypical antipsychotics) for severe aggression
• Mood stabilizers (valproic acid) if mood lability

Sleep Disturbances

• Sleep hygiene education [7]
• Melatonin: 3-10 mg at bedtime; highly effective and safe in children [7]
• Screen for and treat obstructive sleep apnea (polysomnography if suspected) [7]

Educational Support

• Individualized Education Plan (IEP) or 504 Plan in school [7]
• Special education services based on specific deficits [7]
• Occupational therapy, speech therapy, physical therapy as needed [7]

Family and Caregiver Support

• Respite care [7]
• Parent support groups (TSC Alliance, Tuberous Sclerosis Association) [7]
• Genetic counselling [7]
• Transition planning (paediatric to adult care; guardianship/capacity issues) [7]

Genetic Counselling and Family Screening

Genetic Counselling

All TSC patients and families should receive genetic counselling: [1]

• Discuss inheritance pattern (autosomal dominant)
• Explain penetrance (nearly 100%) and variable expressivity
• Recurrence risk:
  • "Affected parent: 50% risk to each offspring"
  • "De novo mutation: Low recurrence risk (~1-2% due to gonadal mosaicism)"
  • "If parental testing not performed: Cannot exclude gonadal mosaicism; recurrence risk ~1-2%"
• Prenatal and preimplantation genetic diagnosis options if familial mutation known [1]

Family Screening

At-Risk Family Members (first-degree relatives of affected individual):

• Clinical evaluation (detailed history, physical exam, Wood's lamp exam) [1]
• Brain MRI [1]
• Renal imaging [1]
• Echocardiogram (children) [1]
• Genetic testing if familial mutation known [1]

If Genetic Mutation Identified:

• Targeted testing for known familial mutation in at-risk relatives [1]
• Negative genetic test excludes TSC (if familial mutation known) [1]

Prenatal Diagnosis: [1]

• Chorionic villus sampling (CVS) or amniocentesis
• Targeted testing for known familial mutation
• Genetic counselling regarding implications of results

Preimplantation Genetic Diagnosis (PGD):

• Option for couples undergoing in vitro fertilization [1]
• Embryo testing for known familial mutation prior to implantation [1]

Transition to Adult Care

Critical Period: Transition from paediatric to adult care (ages 18-25) is high-risk for loss to follow-up and complications [1,7]

Transition Checklist:

• Establish adult care providers (neurology, nephrology, primary care)
• Transfer medical records and surveillance schedule
• Educate patient regarding disease, medications, surveillance needs
• Address legal issues:
  • Capacity assessment
  • Guardianship or power of attorney if intellectual disability precludes independent decision-making
  • Advanced directives
• Vocational planning and disability services
• Reproductive counselling (contraception, pregnancy planning, genetic counselling)

Focus Shift: Adult care emphasizes renal and pulmonary manifestations (major mortality drivers in adults), whereas paediatric care focuses on neurological outcomes [1,9,11]

---

8. Prognosis and Outcomes

Life Expectancy

• Improved survival: Life expectancy has increased substantially with modern management [2,3]
• Many patients live into adulthood: With appropriate surveillance and treatment, many TSC patients survive to ages 40-60 and beyond [2,3]
• Mortality: Leading causes differ by age:
  • "Infancy/childhood: Status epilepticus, SEGA with acute hydrocephalus [2]"
  • "Adulthood: Renal disease (haemorrhage, chronic kidney disease), respiratory failure from LAM [2,9,11]"

Predictors of Outcome

Favourable Prognostic Factors:

• TSC1 mutation (vs. TSC2) [4]
• Absence of infantile spasms [17]
• Early seizure control [6,17]
• Smaller tuber burden [6]
• Normal intellect [7]
• Absence of SEGA [13]
• Small or stable renal AMLs [9]

Unfavourable Prognostic Factors:

• TSC2 mutation (especially large deletions) [4]
• Infantile spasms, especially if treatment delayed [17]
• Refractory epilepsy [6]
• Large tuber burden [6]
• Intellectual disability [7]
• SEGA requiring treatment [13]
• Large or multiple renal AMLs [9]
• LAM in women [11]

Neurological Outcomes

Epilepsy: [6]

• 60-80% have drug-resistant epilepsy [6]
• Seizure freedom: Achieved in 20-40% with medical therapy; 50-70% with epilepsy surgery (if single focus identified) [6,18]
• SUDEP risk: Sudden unexpected death in epilepsy; increased risk in TSC with refractory epilepsy [6]

Intellectual Outcomes: [7,17]

• 40-60% have intellectual disability (mild to profound) [7]
• 30-40% have normal IQ [7]
• Strong inverse correlation with infantile spasms and seizure burden [17]
• Early vigabatrin treatment for infantile spasms improves cognitive outcomes [17]

TAND: [7]

• Autism, ADHD, anxiety, depression common [7]
• Early intervention improves functional outcomes [7]
• Quality of life significantly impacted [7]

Renal Outcomes

• Angiomyolipomas: [9]

  • Risk of haemorrhage increases with size (> 4 cm) [8]
  • mTOR inhibitors reduce AML size and haemorrhage risk [15]
  • Chronic kidney disease develops in 20-30% by adulthood [9]
  • End-stage renal disease in 1-2% [9]

• Renal cell carcinoma: 2-4% incidence; usually detected early with surveillance [9]

Pulmonary Outcomes (Women)

• LAM: [11]
  • Progressive in most if untreated [11]
  • Sirolimus stabilizes lung function [11]
  • "Median time to respiratory failure: Variable (10-20 years from diagnosis) [11]"
  • "Lung transplant outcomes: 50-60% 5-year survival [11]"

Cardiac Outcomes

• Rhabdomyomas: Excellent prognosis; most regress spontaneously [10]
• Rare arrhythmia-related mortality in infancy [10]

Impact of mTOR Inhibitor Therapy on Prognosis

The introduction of everolimus and sirolimus has significantly improved prognosis for TSC patients: [13,14,15]

• SEGA: Avoided neurosurgery in majority; prevented hydrocephalus
• Renal AML: Reduced haemorrhage risk; preserved renal function
• LAM: Stabilized lung function; delayed or prevented transplant
• Overall mortality likely reduced, though long-term data still emerging

Quality of Life

• Highly variable: Depends on neurological severity, seizure control, intellectual function, TAND manifestations [7]
• Major drivers of poor QOL: [7]
  • Refractory epilepsy
  • Intellectual disability
  • Autism spectrum disorder
  • Psychiatric comorbidities
  • Chronic pain (ungual fibromas, renal lesions)
• Improvements with modern care: [1,7]
  • Better seizure control (new ASMs, epilepsy surgery)
  • TAND recognition and intervention
  • mTOR inhibitor therapy
  • Multidisciplinary care coordination

---

9. Complications

---

10. Evidence Base and Guidelines

Key Guidelines

Landmark Trials and Evidence

mTOR Inhibitor Trials

EXIST-1 (Everolimus for SEGA): [13]

• Design: Randomized, placebo-controlled, phase 3 trial
• Population: TSC patients with growing SEGA not requiring immediate surgery
• Intervention: Everolimus vs. placebo
• Primary outcome: SEGA response rate (≥50% volume reduction)
• Results: 35% response rate with everolimus vs. 0% with placebo (pless than 0.0001)
• Conclusion: Everolimus effective for SEGA; now first-line therapy [13]

EXIST-2 (Everolimus for Renal AML): [15]

• Design: Randomized, placebo-controlled, phase 3 trial
• Population: TSC patients or sporadic LAM patients with renal AML ≥3 cm
• Intervention: Everolimus vs. placebo
• Primary outcome: AML response rate (≥50% volume reduction)
• Results: 42% response rate with everolimus vs. 0% with placebo (pless than 0.0001)
• Conclusion: Everolimus effective for reducing AML size; decreases haemorrhage risk [15]

EXIST-3 (Everolimus for Epilepsy): [21]

• Design: Randomized, placebo-controlled, phase 3 trial
• Population: TSC patients ≥2 years with refractory focal-onset seizures
• Intervention: Everolimus (low or high exposure) vs. placebo
• Primary outcome: ≥50% seizure reduction
• Results: ~40% response rate with everolimus vs. ~15% with placebo
• Conclusion: Everolimus effective as adjunctive ASM in TSC-related epilepsy [21]

MILES Trial (Sirolimus for LAM): [11]

• Design: Randomized, placebo-controlled trial
• Population: Women with LAM (TSC-associated or sporadic)
• Intervention: Sirolimus vs. placebo for 12 months
• Primary outcome: Change in FEV1
• Results: Sirolimus stabilized FEV1; placebo group declined. Benefit lost after discontinuation.
• Conclusion: Sirolimus stabilizes lung function in LAM; requires long-term therapy [11]

Epilepsy Trials

FSGE Study (Vigabatrin for Infantile Spasms in TSC): [16]

• Design: Prospective study (not randomized)
• Population: Infants with TSC and new-onset infantile spasms
• Intervention: Vigabatrin
• Results: 95% cessation of spasms within 2 weeks
• Conclusion: Vigabatrin highly effective for infantile spasms in TSC; now first-line [16]

PREVeNT Trial (Vigabatrin to Prevent Infantile Spasms): [17]

• Design: Randomized, placebo-controlled trial
• Population: Infants with TSC less than 6 months old without clinical spasms but with EEG abnormalities
• Intervention: Vigabatrin vs. placebo
• Primary outcome: Incidence of infantile spasms or seizures; neurodevelopmental outcomes
• Results: Vigabatrin delayed onset of spasms and improved developmental outcomes
• Implication: Consideration of early vigabatrin in high-risk infants (not yet standard practice) [17]

Levels of Evidence Summary

---

11. Patient and Layperson Explanation

What is Tuberous Sclerosis Complex?

Tuberous Sclerosis Complex (TSC) is a genetic condition that you are born with. It causes benign (non-cancerous) growths to develop in different parts of the body, including the brain, kidneys, heart, lungs, skin, and eyes. These growths are called hamartomas or tubers. TSC is caused by a change (mutation) in one of two genes: TSC1 or TSC2.

Is it common?

TSC affects about 1 in 6,000 to 10,000 babies. It can affect anyone, regardless of ethnicity or gender.

How did my child get TSC?

TSC is an inherited condition that runs in families. However, in most cases (about 7 out of 10), the gene change occurs for the first time in the child—this is called a "de novo" or "new" mutation. This means the parents do not have TSC, and it was not passed down from them. In about 3 out of 10 cases, the child inherits the gene change from a parent who has TSC.

If you or your partner has TSC, there is a 50% chance (1 in 2) that each of your children will inherit it.

What are the symptoms?

TSC affects each person differently—even within the same family. Some people have mild symptoms, while others are more severely affected. The most common problems include:

Brain and Seizures:

• About 8 out of 10 people with TSC develop seizures (epilepsy). In babies, a specific type called infantile spasms is common. These look like sudden jerking movements, often in clusters.
• Some people develop learning difficulties, autism, or behavioural problems (such as ADHD, anxiety).

Skin:

• White patches (called ash-leaf spots) on the skin—often the earliest sign. A special ultraviolet light (Wood's lamp) makes them easier to see.
• Small bumps on the face (angiofibromas) that look like acne but appear around ages 2-5.
• Thickened skin patches on the lower back (Shagreen patches) or growths around the toenails.

Kidneys:

• Benign kidney tumours called angiomyolipomas. These can grow large and sometimes bleed, which can be serious.

Heart:

• Benign heart tumours called rhabdomyomas. These are often seen on ultrasound before the baby is born. Most shrink on their own by age 2-4.

Lungs (in women):

• A lung condition called LAM (lymphangioleiomyomatosis) can develop in adult women, causing breathing problems.

How is TSC diagnosed?

TSC is diagnosed based on:

• Physical examination: Looking for skin changes and other features.
• Imaging scans: MRI of the brain, ultrasound or MRI of the kidneys, and other tests.
• Genetic testing: A blood test to look for changes in the TSC1 or TSC2 genes.

Your doctor may also check your child's heart (echocardiogram) and eyes.

Is there treatment?

Yes! While there is no cure, there are excellent treatments to manage TSC and prevent complications:

For Seizures:

• Anti-seizure medicines can control seizures in many people. For infantile spasms, a medicine called vigabatrin works very well.
• If medicines don't work, brain surgery to remove the part of the brain causing seizures may be an option.

For Brain and Kidney Tumours:

• A medicine called everolimus can shrink brain tumours (called SEGAs) and kidney tumours. It works by blocking the signal that makes these tumours grow.
• Surgery may be needed if tumours cause sudden problems (like blocking fluid drainage in the brain).

For Lung Problems (LAM in women):

• A medicine called sirolimus helps stabilize lung function.

For Learning and Behavioural Problems:

• Early intervention, special education, therapy (speech, occupational, behavioural), and sometimes medicines can help.

For Skin Problems:

• A cream containing sirolimus can improve facial bumps. Laser treatment is also an option.

What kind of follow-up is needed?

People with TSC need lifelong regular check-ups to watch for problems:

• Brain MRI scans every 1-3 years to check for brain tumours.
• Kidney scans every 1-3 years to check kidney tumours.
• Lung scans for women starting at age 18.
• Regular check-ups with doctors (neurologist, kidney doctor, skin doctor, etc.).

What is the outlook?

The outlook for TSC varies greatly depending on how severe the condition is:

• Many people with TSC live long, fulfilling lives.
• The biggest challenges are usually seizures and learning/behavioural problems. Controlling seizures early improves brain development.
• With modern treatments (like everolimus for tumours), serious complications can often be prevented or managed.
• Some people have very mild TSC and may not even know they have it until adulthood.

Can TSC be passed on to future children?

Yes. If you have TSC, each of your children has a 50% chance (1 in 2) of inheriting it. Genetic counselling can help you understand the risks and options, including genetic testing during pregnancy or before pregnancy (preimplantation genetic diagnosis).

Where can I get support?

• TSC Alliance (USA): www.tscalliance.org
• Tuberous Sclerosis Association (UK): www.tuberous-sclerosis.org
• Your medical team can connect you with support groups and resources.

Key Takeaways

• TSC is a genetic condition causing benign growths in multiple organs.
• Seizures and brain-related problems are the most common challenges.
• Effective treatments exist (medicines like vigabatrin, everolimus, sirolimus; surgery when needed).
• Regular monitoring and a team of doctors are essential.
• With proper care, many people with TSC lead healthy, fulfilling lives.

---

12. Examination Focus

High-Yield Topics for Postgraduate Exams (MRCP, MRCPCH, FRACP, USMLE)

Written Exam (MCQ/SBA) High-Yield Facts

1. First-line treatment for infantile spasms in TSC: Vigabatrin [16,17]

2. Vogt's Triad: Epilepsy, intellectual disability, facial angiofibromas (adenoma sebaceum)—but only 30% have all three; not required for diagnosis [2,5]

3. Earliest cutaneous sign: Hypopigmented macules (ash-leaf spots); use Wood's lamp [1,12]

4. Most common fetal cardiac tumour: Rhabdomyoma (50% of cases have TSC) [10]

5. Brain tumour in TSC causing hydrocephalus: Subependymal giant cell astrocytoma (SEGA), located near foramen of Monro [13,14]

6. First-line treatment for growing SEGA: Everolimus (mTOR inhibitor) [13,14]

7. Renal AML haemorrhage risk threshold: > 3-4 cm diameter [8,9]

8. Gene mutations: TSC1 (hamartin, chromosome 9q34); TSC2 (tuberin, chromosome 16p13) [1,2]

9. mTOR pathway: TSC1/TSC2 complex inhibits mTOR; loss causes constitutive mTOR activation [2,20]

10. Inheritance: Autosomal dominant; 70% de novo, 30% familial [1,3]

11. Genotype-phenotype: TSC2 mutations generally more severe than TSC1 [4]

12. Pulmonary LAM: Affects almost exclusively adult women with TSC; sirolimus is treatment [11]

13. Diagnostic criteria (2021): 2 major OR 1 major + 2 minor OR pathogenic TSC1/TSC2 mutation [1]

14. LAM + renal AML: Counts as ONE major feature (not two) [1]

15. "Candle guttering" on brain MRI: Subependymal nodules [5]

Clinical Exam (PACES/OSCE) High-Yield Scenarios

Station: Dermatology/Neurology

Scenario: Examine this patient's skin.

Findings:

• Hypopigmented macules (ash-leaf spots)—request Wood's lamp
• Facial angiofibromas (nasolabial folds, cheeks)
• Shagreen patch (lower back)
• Periungual fibromas (toenails)

Diagnosis: Tuberous sclerosis complex

Discussion Points:

• What other systems can be affected? (Brain, kidneys, heart, lungs, eyes)
• What is the inheritance pattern? (Autosomal dominant)
• What brain complications can occur? (Seizures, cortical tubers, SEGA, intellectual disability)
• What is the first-line treatment for infantile spasms? (Vigabatrin)
• What surveillance is needed? (MRI brain, renal imaging, TAND screening)

Station: Neurology

Scenario: This 8-month-old infant presents with episodes of sudden jerking in clusters, particularly on waking.

History: Infantile spasms

Examination: White patches on skin (ash-leaf spots)

Diagnosis: TSC with infantile spasms (West syndrome)

Investigations: EEG (hypsarrhythmia), brain MRI (cortical tubers), genetic testing

Management: Vigabatrin urgently; ophthalmology monitoring for retinal toxicity

Prognosis: Early treatment critical for neurodevelopmental outcomes

Viva Voce High-Yield Questions

Question 1: What is the molecular pathophysiology of TSC?

Model Answer:

• TSC1 and TSC2 genes encode hamartin and tuberin proteins
• These form a complex that inhibits mTOR (mechanistic target of rapamycin), a master regulator of cell growth
• TSC1/TSC2 mutations cause loss of mTOR inhibition → constitutive mTOR activation
• Uncontrolled mTOR drives cell growth and proliferation → hamartomas in multiple organs
• mTOR inhibitors (everolimus, sirolimus) restore control of mTOR pathway [2,20]

Question 2: A 15-year-old with TSC has a growing SEGA on serial MRI. What are your management options?

Model Answer:

• First-line: Everolimus (mTOR inhibitor)
  • Target trough 5-15 ng/mL
  • "EXIST-1 trial: 35% achieved ≥50% volume reduction"
  • Monitor for adverse effects (stomatitis, infections, cytopenias)
  • Requires long-term therapy
• Second-line: Neurosurgical resection
  • "Indications: Acute hydrocephalus, everolimus failure/contraindication"
  • "Approaches: Transcallosal or transcortical"
  • Gross total resection is curative
  • "Risks: Hemiparesis, memory deficits, fornix injury [13,14]"

Question 3: How do you distinguish a subependymal nodule (SEN) from a SEGA?

Model Answer:

• SEN:
  • Stable size on serial imaging (less than 1 cm typically)
  • Does not grow
  • Benign; no treatment needed
• SEGA:
  • Size > 1 cm near foramen of Monro
  • Shows serial growth on consecutive MRI scans
  • Avidly enhances with gadolinium
  • May cause hydrocephalus
  • Requires treatment (everolimus or surgery) [5,13,14]

Question 4: What is the "two-hit hypothesis" in TSC?

Model Answer:

• TSC follows Knudson's two-hit hypothesis for tumour suppressor genes
• First hit: Germline mutation in TSC1 or TSC2 (inherited or de novo)—present in all cells
• Second hit: Somatic mutation of the second allele in specific cells
• Loss of both alleles (loss of heterozygosity) causes focal hamartoma development
• Explains why lesions are multifocal but discrete (not diffuse) [19]

Question 5: What are TSC-associated neuropsychiatric disorders (TAND) and how common are they?

Model Answer:

• TAND affects 90% of TSC patients but only 20% receive treatment
• Domains:
  • "Behavioural: Aggression, self-injury, sleep disturbance"
  • "Psychiatric: Autism (40-50%), ADHD (30-50%), anxiety (30-50%), depression (30%)"
  • "Intellectual: Intellectual disability (40-60%); 30-40% have normal IQ"
  • "Academic: Learning disabilities even with normal IQ"
• Screening: Annual TAND checklist recommended
• Management: Multidisciplinary (behavioural therapy, medications, educational support) [1,7]

---

13. Advanced Topics

Knudson's Two-Hit Hypothesis and TSC

TSC1 and TSC2 are tumour suppressor genes. Tumorigenesis in TSC follows the classic Knudson two-hit model: [19]

1. First hit: Germline mutation (inherited or de novo) in TSC1 or TSC2—present in every cell of the body
2. Second hit: Somatic mutation (acquired during development or later) inactivates the second allele in specific cells

Result: Cells with biallelic inactivation (loss of heterozygosity) have complete loss of TSC1/TSC2 function → uncontrolled mTOR activation → hamartoma formation at that site [19]

Clinical implications:

• Explains multifocal but discrete lesions (only cells with second hit develop tumours)
• Explains phenotypic variability (timing and location of somatic mutations are random)
• Implies hamartomas are clonal proliferations arising from single cells [19]

Mosaicism in TSC

Somatic mosaicism: [1]

• Individual has two populations of cells: some with TSC1/TSC2 mutation, some without
• Results from post-zygotic mutation during early development
• May present with milder, localized manifestations
• Genetic testing of blood may be negative (mutation only in subset of cells)
• May require testing of affected tissue (e.g., skin biopsy) to detect mutation

Gonadal (germline) mosaicism: [1]

• Mutation present in germ cells (sperm or eggs) but not somatic cells
• Parent appears clinically unaffected and blood genetic testing negative
• Can transmit mutation to offspring
• Explains recurrence in families where both parents test negative
• Recurrence risk ~1-2% due to gonadal mosaicism [1]

TSC2-PKD1 Contiguous Gene Deletion Syndrome

• Location: TSC2 gene and PKD1 gene (polycystic kidney disease 1) are adjacent on chromosome 16p13 [9]
• Large deletion can encompass both genes [9]
• Phenotype:
  • Severe early-onset polycystic kidney disease (much earlier than typical autosomal dominant PKD)
  • TSC features (often severe due to TSC2 involvement)
  • Chronic kidney disease in childhood; often progresses to ESRD [9]
• Management: Aggressive renal monitoring; may require early dialysis or transplantation [9]

TAND Pathophysiology

TAND manifestations correlate with: [7]

• Tuber burden and location: Frontal and temporal tuber burden correlates with autism and ADHD
• Epilepsy burden: Seizures (especially infantile spasms) strongly predict intellectual disability and autism
• mTOR dysregulation: Aberrant mTOR signalling impairs synaptic plasticity, dendritic spine morphology, and neuronal connectivity [7]

Animal models (Tsc1/Tsc2 knockout mice):

• Demonstrate social deficits, repetitive behaviours, learning impairments
• mTOR inhibitors (rapamycin) in early development partially rescue behavioural phenotypes
• Suggests potential for early mTOR inhibitor therapy to prevent TAND (under investigation) [7]

Novel and Investigational Therapies

Cannabidiol (CBD) for Epilepsy:

• Case reports suggest benefit in TSC-related epilepsy
• Randomized trial (GWPCARE6) in TSC-related epilepsy showed modest seizure reduction
• Not yet standard therapy; further study needed

mTOR Inhibitors for TAND:

• Preclinical data suggest potential neurocognitive benefit
• Small clinical studies show mixed results
• Ongoing trials investigating early everolimus for neurodevelopmental outcomes

Gene Therapy:

• Theoretical potential to restore TSC1/TSC2 function
• Technical challenges due to large gene size and multisystem involvement
• Preclinical stage

Transition to Adult Care: Key Challenges

Medical:

• Shift in focus from neurological to renal and pulmonary manifestations [1,9,11]
• LAM surveillance and management in women [11]
• Chronic kidney disease management [9]

Psychosocial:

• Many TSC adults have intellectual disability → capacity and guardianship issues [7]
• Vocational challenges [7]
• Independent living often not possible [7]
• Reproductive counselling (50% transmission risk) [1]

Systemic:

• Loss to follow-up common during transition period [1]
• Need coordinated handover from paediatric to adult providers [1]

---

14. References

Primary Sources

1. Northrup H, Aronow ME, Bebin EM, et al.; International Tuberous Sclerosis Complex Consensus Group. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50-66. PMID: 34399110. DOI: 10.1016/j.pediatrneurol.2021.07.011

2. Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. PMID: 27226234. DOI: 10.1038/nrdp.2016.35

3. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657-668. PMID: 18722871. DOI: 10.1016/S0140-6736(08)61279-9

4. Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9(2):88-100. PMID: 17304050. DOI: 10.1097/GIM.0b013e31803068c7

5. Russo C, Nastro A, Cicala D, et al. Neuroimaging in tuberous sclerosis complex. Childs Nerv Syst. 2020;36(10):2497-2509. PMID: 32519125. DOI: 10.1007/s00381-020-04725-0

6. DiMario FJ Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62(3):633-648. PMID: 26022167. DOI: 10.1016/j.pcl.2015.03.005

7. de Vries PJ, Whittemore VH, Leclezio L, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015;52(1):25-35. PMID: 25532776. DOI: 10.1016/j.pediatrneurol.2014.10.004

8. Flum AS, Hamoui N, Said MA, et al. Update on the diagnosis and management of renal angiomyolipoma. J Urol. 2016;195(4 Pt 1):834-846. PMID: 26612197. DOI: 10.1016/j.juro.2015.07.126

9. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant. 2016;31(1):111-119. PMID: 26156073. DOI: 10.1093/ndt/gfv249

10. Knilans TK, Chard M, Moss J, Kingswood JC. Cardiac manifestations of tuberous sclerosis complex. Pediatr Cardiol. 2017;38(7):1456-1463. PMID: 28741048. DOI: 10.1007/s00246-017-1688-5

11. McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021;9(11):1313-1327. PMID: 34461049. DOI: 10.1016/S2213-2600(21)00228-9

12. Darling TN, Moss J, Mausner M, Goldberg NS. Skin manifestations of tuberous sclerosis complex. Dermatol Clin. 2017;35(1):37-45. PMID: 27890237. DOI: 10.1016/j.det.2016.07.003

13. Franz DN, Belousova E, Sparagana S, et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One. 2016;11(6):e0158476. PMID: 27351628. DOI: 10.1371/journal.pone.0158476

14. Ebrahimi-Fakhari D, Franz DN. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). Expert Opin Pharmacother. 2020;21(10):1087-1095. PMID: 32338549. DOI: 10.1080/14656566.2020.1746273

15. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817-824. PMID: 23312829. DOI: 10.1016/S0140-6736(12)61767-X

16. Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14(2):146-149. PMID: 19836964. DOI: 10.1016/j.ejpn.2009.03.003

17. Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15(5):424-431. PMID: 21507691. DOI: 10.1016/j.ejpn.2011.03.010

18. Jansen FE, Braams O, Vincken KL, et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology. 2008;70(12):908-915. PMID: 18032745. DOI: 10.1212/01.wnl.0000280578.99900.96

19. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356. PMID: 17005952. DOI: 10.1056/NEJMra055323

20. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976. PMID: 28283069. DOI: 10.1016/j.cell.2017.02.004

21. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153-2163. PMID: 27613521. DOI: 10.1016/S0140-6736(16)31419-2

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current guidelines and primary literature when making treatment decisions.